中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(10): 2296-2301

Clinical features of Polygonum multiflorum preparation-related liver injury with or without positive autoantibody

DOI: 10.3969/j.issn.1001-5256.2022.10.018
  • 1.

    The First Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100700, China

  • 2.

    Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding:

Capital's Funds for Health Improvement and Research (2018-1-2172);

National Science and Technology Major Project (2018ZX10723203);

Capacity Building of TCM and WESTERN Medicine Clinical Collaboration in Major and Difficult Diseases in 2019 (2019-285)

More Information
  • Corresponding author: ZHOU Guiqin, zhouguiqin@ccmu.edu.cn(ORCID: 0000-0002-1035-0181)
  • Received Date: 2022-02-11
  • Accepted Date: 2022-04-19
  • Published Date: 2022-10-20
    Abstract
  •   Objective  To investigate the clinical features of patients with Polygonum multiflorum preparation-related liver injury with or without positive autoantibody based on propensity score matching, as well as the influence of positive autoantibody on the prognosis of such patients.  Methods  A total of 364 patients with Polygonum multiflorum preparation-related liver injury who were hospitalized in Beijing Ditan Hospital, Capital Medical University, from August 2008 to June 2021 were enrolled, and according to whether autoantibodies were detected, they were divided into negative autoantibody group (H0 group) with 157 patients and positive autoantibody group (H1 group) with 207 patients. After adjustment for confounding factors by propensity score matching, the two groups were compared in terms of biochemical parameters, severity of liver injury, classification of liver injury, and disease outcome when liver injury reached the peak. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test or the Mann-Whitney U rank sum test was used for comparison of categorical data or ranked data between two groups. The Cox regression model was used to analyze the influencing factors for liver function recovery. The Kaplan-Meier method was used to plot survival curves, and the Log-rank test was used for comparison between groups.  Results  A total of 98 pairs of cases were successfully matched after propensity score matching. Comparison of biochemical parameters between the two groups at the peak of liver injury showed that compared with the H0 group, the H1 group had significantly higher levels of alkaline phosphatase (ALP), globulin, and total bile acid and a significantly lower level of albumin (all P < 0.05). There was no significant difference in the classification of liver injury between the two groups (P > 0.05), and there was a significant difference in the severity of liver injury between the two groups (Z=1.710, P=0.045). Antinuclear antibody (ANA) was the main positive autoantibody and accounted for 49%, and there was a significant difference in the severity of liver injury between the patients with different ANA antibody titers (Z=20.252, P=0.001). Comparison of disease outcome in terms of whether liver function returned to normal within 6 months showed that the normalization rate of liver function within 6 months was 90.8% in the H0 group and 75.5% in the H1 group, and the H1 group had a lower normalization rate of liver function (χ2=8.199, P=0.004). The Cox regression analysis showed that autoantibody (hazard ratio [HR]=5.248, 95% confidence interval [CI]: 1.554-17.718, P=0.008) and ALP (HR=1.013, 95%CI: 1.002-1.025, P=0.026) were independent risk factors for liver function recovery. The Kaplan-Meier survival curve analysis showed that compared with the negative autoantibody group, the positive autoantibody group had a significantly higher risk of failure in liver function recovery after 6 months (χ2=8.802, P=0.003).  Conclusion  Autoantibody has no significant influence on the classification of Polygonum multiflorum preparation-related liver injury, and compared with the patients with negative autoantibody, the patients with positive autoantibody tend to have more severe liver injury and a more obvious tendency of chronicity.

     

    • FullText(HTML)
  • loading
    • References(14)
  • [1]
    Branch of Hepatobiliary Diseases, China Association of Chinese Medicine; Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol, 2016, 32(5): 835-843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.

    中华中医药学会肝胆病分会, 中华中医药学会中成药分会. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32(5): 835-843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.
    [2]
    AN XD, WEI Y, LIAN FM. Clinical application and dosage of fleeceflower root[J]. J Changchun Univ Chin Med, 2020, 36(2): 219-221. DOI: 10.13463/j.cnki.cczyy.2020.02.005.

    安学冬, 韦宇, 连凤梅. 何首乌的临床应用及其用量[J]. 长春中医药大学学报, 2020, 36(2): 219-221. DOI: 10.13463/j.cnki.cczyy.2020.02.005.
    [3]
    CAO YN, WANG NN, ZHOU GQ, et al. Analysis of influencing factors of clinical outcome in 186 patients with the drug-in-duced liver injury with positive autoantibodies[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31(1): 26-29, 33. DOI: 10.3969/j.issn.1005-0264.2021.01.007.

    曹亦楠, 王娜娜, 周桂琴, 等. 自身抗体阳性药物性肝损伤患者临床转归影响因素分析[J]. 中西医结合肝病杂志, 2021, 31(1): 26-29, 33. DOI: 10.3969/j.issn.1005-0264.2021.01.007.
    [4]
    YIN JY. Brief analysis of clinical value of detecting autoimmune antibody in patients with drug-induced liver injury[J]. China Prac Med, 2021, 16(7): 77-79. DOI: 10.14163/j.cnki.11-5547/r.2021.07.031.

    尹金燕. 浅析药物性肝损伤患者检测自身免疫性抗体的临床价值[J]. 中国实用医药, 2021, 16(7): 77-79. DOI: 10.14163/j.cnki.11-5547/r.2021.07.031.
    [5]
    Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis (2021)[J]. J Clin Hepatol, 2022, 38(1): 42-49. DOI: 10.3760/cma.j.cn112138-20211112-00796.

    中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 42-49. DOI: 10.3760/cma.j.cn112138-20211112-00796.
    [7]
    SRIVASTAVA A, MAGGS JL, ANTOINE DJ, et al. Role of reactive metabolites in drug-induced hepatotoxicity[J]. Handb Exp Pharmacol, 2010, 196: 165-194. DOI: 10.1007/978-3-642-00663-0_7.
    [8]
    VINKEN M, MAES M, VANHAECKE T, et al. Drug-induced liver injury: mechanisms, types and biomarkers[J]. Curr Med Chem, 2013, 20(24): 3011-3021. DOI: 10.2174/0929867311320240006.
    [9]
    FONTANA RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J]. Gastroenterology, 2014, 146(4): 914-928. DOI: 10.1053/j.gastro.2013.12.032.
    [10]
    REN MX, CHEN J, HUANG CY, et al. The clinical and pathological characteristics of drug-induced liver injury accompanied by autoimmune phenomena[J]. J China-Japan Friendship Hosp, 2018, 32(5): 279-283. DOI: 10.3969/j.issn.1001-0025.2018.05.006.

    任美欣, 陈杰, 黄春洋, 等. 伴自身免疫现象的药物性肝损伤的临床和病理特点[J]. 中日友好医院学报, 2018, 32(5): 279-283. DOI: 10.3969/j.issn.1001-0025.2018.05.006.
    [11]
    DENG ML, YANG LJ, SHI XL, et al. The immunologic and clinic features of 128 cases of drug-induced liver injury[J]. Chin Hosp Pharm J, 2019, 39(1): 63-66. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.01.14.

    邓茂林, 杨丽君, 石先利, 等. 128例药物性肝损伤患者的免疫特点及临床分析[J]. 中国医院药学杂志, 2019, 39(1): 63-66. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.01.14.
    [12]
    STINE JG, CHALASANI N. Chronic liver injury induced by drugs: a systematic review[J]. Liver Int, 2015, 35(11): 2343-2353. DOI: 10.1111/liv.12958.
    [13]
    MENG YK, LI CY, LI RY, et al. Cis-stilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR-γ[J]. Acta Pharmacol Sin, 2017, 38(10): 1340-1352. DOI: 10.1038/aps.2017.32.
    [14]
    TENG SS, SUN Z, QIU Y, et al. Investigation, optimization and evaluation of traditional Chinese medicine processing technology of nine steaming and nine drying[J]. J Changchun Univ Chin Med, 2022, 38(1): 109-113. DOI: 10.13463/j.cnki.cczyy.2022.01.026.

    滕杉杉, 孙震, 邱野, 等. 中药炮制传统工艺九蒸九晒的调研、优化及评价[J]. 长春中医药大学学报, 2022, 38(1): 109-113. DOI: 10.13463/j.cnki.cczyy.2022.01.026.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(8)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (431) PDF downloads(53) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return